JP2024519451A5 - - Google Patents
Info
- Publication number
- JP2024519451A5 JP2024519451A5 JP2023563991A JP2023563991A JP2024519451A5 JP 2024519451 A5 JP2024519451 A5 JP 2024519451A5 JP 2023563991 A JP2023563991 A JP 2023563991A JP 2023563991 A JP2023563991 A JP 2023563991A JP 2024519451 A5 JP2024519451 A5 JP 2024519451A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- conjugate
- pharmaceutically acceptable
- antisense oligomer
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163182327P | 2021-04-30 | 2021-04-30 | |
| US63/182,327 | 2021-04-30 | ||
| US202163249721P | 2021-09-29 | 2021-09-29 | |
| US63/249,721 | 2021-09-29 | ||
| PCT/US2022/026887 WO2022232478A1 (en) | 2021-04-30 | 2022-04-29 | Treatment methods for muscular dystrophy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024519451A JP2024519451A (ja) | 2024-05-14 |
| JP2024519451A5 true JP2024519451A5 (enExample) | 2025-05-02 |
Family
ID=81749386
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023563991A Pending JP2024519451A (ja) | 2021-04-30 | 2022-04-29 | 筋ジストロフィーのための治療法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12286630B2 (enExample) |
| EP (1) | EP4330395A1 (enExample) |
| JP (1) | JP2024519451A (enExample) |
| KR (1) | KR20240004609A (enExample) |
| AU (1) | AU2022267324A1 (enExample) |
| BR (1) | BR112023021849A2 (enExample) |
| CA (1) | CA3216839A1 (enExample) |
| CO (1) | CO2023016203A2 (enExample) |
| IL (1) | IL307937A (enExample) |
| MX (1) | MX2023012559A (enExample) |
| WO (1) | WO2022232478A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202100928QA (en) | 2018-08-02 | 2021-02-25 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| CA3108282A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5217866A (en) | 1985-03-15 | 1993-06-08 | Anti-Gene Development Group | Polynucleotide assay reagent and method |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
| WO1986005519A1 (en) | 1985-03-15 | 1986-09-25 | James Summerton | Polynucleotide assay reagent and method |
| US5521063A (en) | 1985-03-15 | 1996-05-28 | Antivirals Inc. | Polynucleotide reagent containing chiral subunits and methods of use |
| US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
| EP0786522A2 (en) | 1992-07-17 | 1997-07-30 | Ribozyme Pharmaceuticals, Inc. | Enzymatic RNA molecules for treatment of stenotic conditions |
| US5820873A (en) | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
| US5753613A (en) | 1994-09-30 | 1998-05-19 | Inex Pharmaceuticals Corporation | Compositions for the introduction of polyanionic materials into cells |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| WO1999042091A2 (en) | 1998-02-19 | 1999-08-26 | Massachusetts Institute Of Technology | Use of polycations as endosomolytic agents |
| US6683173B2 (en) | 1998-04-03 | 2004-01-27 | Epoch Biosciences, Inc. | Tm leveling methods |
| WO2001047496A1 (en) | 1999-12-29 | 2001-07-05 | Mixson A James | Histidine copolymer and methods for using same |
| US7070807B2 (en) | 1999-12-29 | 2006-07-04 | Mixson A James | Branched histidine copolymers and methods for using same |
| EP2392660A3 (en) | 2002-11-25 | 2012-03-28 | Masafumi Matsuo | ENA Nucleic Acid Drugs Modifying Splicing in mRNA Precursor |
| US7468418B2 (en) | 2003-04-29 | 2008-12-23 | Avi Biopharma., Inc. | Compositions for enhancing transport of molecules into cells |
| WO2009005793A2 (en) | 2007-06-29 | 2009-01-08 | Avi Biopharma, Inc. | Tissue specific peptide conjugates and methods |
| US8299206B2 (en) | 2007-11-15 | 2012-10-30 | Avi Biopharma, Inc. | Method of synthesis of morpholino oligomers |
| US8076476B2 (en) | 2007-11-15 | 2011-12-13 | Avi Biopharma, Inc. | Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits |
| WO2009127230A1 (en) | 2008-04-16 | 2009-10-22 | Curevac Gmbh | MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION |
| TWI541024B (zh) | 2010-09-01 | 2016-07-11 | 日本新藥股份有限公司 | 反義核酸 |
| ES2607603T3 (es) | 2010-09-30 | 2017-04-03 | Nippon Shinyaku Co., Ltd. | Derivado de ácido morfolino nucleico |
| US9161948B2 (en) | 2011-05-05 | 2015-10-20 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| CA3092114A1 (en) | 2011-05-05 | 2012-11-08 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| CA2861247C (en) | 2011-12-28 | 2021-11-16 | Nippon Shinyaku Co., Ltd. | Antisense nucleic acids |
| DK3118311T3 (en) | 2014-03-12 | 2019-03-11 | Nippon Shinyaku Co Ltd | Antisense nucleic acid |
| MX373052B (es) | 2014-06-17 | 2020-05-11 | Nippon Shinyaku Co Ltd | Acidos nucleicos antisentido. |
| HUE050061T2 (hu) | 2015-09-15 | 2020-12-28 | Nippon Shinyaku Co Ltd | Antiszensz nukleinsav |
| IL295755A (en) | 2015-10-09 | 2022-10-01 | Wave Life Sciences Ltd | Oligonucleotide compositions and methods thereof |
| MX2018016253A (es) | 2016-07-05 | 2019-09-09 | Biomarin Tech Bv | Oligonucleotidos de conmutacion o modulacion de empalme de pre-arnm que comprenden radicales de andamio biciclicos, con caracteristicas mejoradas para el tratamiento de trastornos geneticos. |
| ES3038159T3 (en) | 2016-11-16 | 2025-10-09 | Academisch Ziekenhuis Leiden | Substances for targeting various selected organs or tissues |
| KR102810425B1 (ko) | 2016-12-19 | 2025-05-21 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 근육 이상증에 대한 엑손 스킵핑 올리고머 결합체 |
| PT3554552T (pt) | 2016-12-19 | 2022-10-03 | Sarepta Therapeutics Inc | Conjugados de oligómero de skipping de exão para distrofia muscular |
| KR20240006023A (ko) | 2016-12-19 | 2024-01-12 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 근육 이상증에 대한 엑손 스킵핑 올리고머 결합체 |
| MX2019008199A (es) | 2017-01-06 | 2019-11-25 | Avidity Biosciences Llc | Composiciones de acido nucleico polipeptido y metodos de induccion de la omision de exon. |
| MX2020003130A (es) | 2017-09-22 | 2020-09-25 | Avidity Biosciences Inc | Composiciones y metodos de induccion de salto de exon en acidos nucleicos-polipeptidos. |
| CN112399849A (zh) | 2018-06-26 | 2021-02-23 | 日本新药株式会社 | 含有反义寡核苷酸的组合物及其在迪谢内肌营养不良症的治疗中的用途 |
| CA3108282A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| SG11202103938UA (en) | 2018-11-02 | 2021-05-28 | Biomarin Tech Bv | Bispecific antisense oligonucleotides for dystrophin exon skipping |
| CN113660938A (zh) | 2019-01-30 | 2021-11-16 | 国立研究开发法人国立精神·神经医疗研究中心 | 核酸递送复合物 |
| WO2020214763A1 (en) * | 2019-04-18 | 2020-10-22 | Sarepta Therapeutics, Inc. | Compositions for treating muscular dystrophy |
| WO2020219820A1 (en) | 2019-04-25 | 2020-10-29 | Avidity Biosciences, Inc. | Nucleic acid compositions and methods of multi-exon skipping |
-
2022
- 2022-04-29 IL IL307937A patent/IL307937A/en unknown
- 2022-04-29 BR BR112023021849A patent/BR112023021849A2/pt unknown
- 2022-04-29 CA CA3216839A patent/CA3216839A1/en active Pending
- 2022-04-29 WO PCT/US2022/026887 patent/WO2022232478A1/en not_active Ceased
- 2022-04-29 JP JP2023563991A patent/JP2024519451A/ja active Pending
- 2022-04-29 EP EP22724552.9A patent/EP4330395A1/en active Pending
- 2022-04-29 AU AU2022267324A patent/AU2022267324A1/en not_active Abandoned
- 2022-04-29 MX MX2023012559A patent/MX2023012559A/es unknown
- 2022-04-29 US US17/732,757 patent/US12286630B2/en active Active
- 2022-04-29 KR KR1020237040520A patent/KR20240004609A/ko active Pending
-
2023
- 2023-11-29 CO CONC2023/0016203A patent/CO2023016203A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024519451A5 (enExample) | ||
| JP6918724B2 (ja) | 急性骨髄性白血病（ａｍｌ）のための新規併用治療 | |
| US7553830B2 (en) | Compositions for the delivery of negatively charged molecules | |
| US20090298943A1 (en) | Use of creatine analogues and creatine kinase modulators for the prevention and treatment of obesity and its related disorders | |
| US20030232793A1 (en) | Use of creatine analogues and creatine kinase modulators for the prevention and treatment of glucose metabolic disorders | |
| US20160256529A1 (en) | Combination therapy | |
| JP2022526763A5 (enExample) | ||
| CN114376970A (zh) | Etelcalcetide (AMG 416)的稳定的液体制剂 | |
| US20070037740A1 (en) | Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis | |
| US20130281419A1 (en) | Therapeutic Uses for an Aminosterol Compound | |
| WO2009075813A1 (en) | Treatment of melanoma with alpha thymosin peptides in combination with antibodies against cytotoxic t lymphocyte-associated antigen 4 (ctla4) | |
| US20080026077A1 (en) | Methods and compositions of gene delivery agents for systemic and local therapy | |
| EP0946177B1 (en) | METHOD OF INHIBITING BIOSYNTHESIS OF EIf5A | |
| JP2005511721A (ja) | エポチロンを含む組成物およびカルチノイド症候群の治療のためのそれらの使用 | |
| CN1278785A (zh) | 单异羟肟酯酯的钒络合物和含其的药用组合物 | |
| US20120302503A1 (en) | PEPTIDES FOR PREVENTING OR TREATING A DISEASE OR DISORDER ASSOCIATED WITH CBP OR p300 MISREGULATION, AND METHODS FOR USE AND IDENTIFICATION THEREOF | |
| EP2236145B1 (en) | Pharmaceutical composition and combined agent | |
| JP2022552378A5 (enExample) | ||
| AU782304B2 (en) | Methods and compositions for reducing serum phosphate levels | |
| EP0715850B1 (en) | Use of proline and/or derivatives as an antihepatitis agent | |
| US11524078B2 (en) | Water-soluble macromolecular derivative of Venetoclax | |
| US6624146B1 (en) | Pharmaceutical compositions containing fibroblast growth factor-related peptides | |
| US20240218365A1 (en) | Formulation of an antisense oligomer conjugate | |
| US7026338B2 (en) | Pharmaceutical nitrones | |
| HU224715B1 (en) | Liposomes containing multiple branch peptide constructions for use against human immunodeficiency virus |